Loading
TaiRx
TaiRx is a Taiwan-based biotechnology company that leads 3 cancer trials in OnCo, testing the oral anti-cancer agent CVM-1118 (foslinanib) in hepatocellular carcinoma, neuroendocrine tumours, pancreatic ductal adenocarcinoma and advanced solid tumours.
Also called: 台睿生物科技
Overview
TaiRx is a Taipei-based new drug development company. Its lead candidate CVM-1118 (foslinanib) is an oral anti-cancer agent in phase 2 for neuroendocrine tumours and hepatocellular carcinoma, and it also markets Zelnite, an injectable selenium product approved in Taiwan. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07521852 (phase 2, A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and...), NCT05257590 (phase 2, CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma) and NCT03600233 (phase 2, Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Taipei, TW
Scorecard
All companies#49of 1245 companies, score 73
- approved products +12
- targets +2
- modalities +2
- regions +7
- 24-month regulatory events +20
- registry trials +30
2 approved, 0 in phase 3, 0 earlier, 1 targets, 1,907 registry studies. Formula on the scorecards page.
Type
Biotech · TPEx:6580
Stage
Public
Website
Founded
2011
Products
2ApprovedMonoclonal antibody (anti-PD-1, IgG4)
Sintilimab · Tyvyt
Sintilimab is Innovent's PD-1 antibody, approved in China since 2018 for Hodgkin lymphoma and then, on the ORIENT trials, for first-line lung, liver, oesophageal and stomach cancer. In 2022 the FDA rejected its lung cancer application because a China-only trial against chemotherapy did not fit US practice, defining the agency's stance on single-country data.
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
Nivolumab was the second PD-1 blocker and is often combined with ipilimumab. Long-term data show about half of advanced melanoma patients alive at 10 years on the combination.
Connected
8Similar pages
- TrialA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Shares Sintilimab, Hepatocellular carcinoma.
- TrialStudy of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Shares Sintilimab, Hepatocellular carcinoma.
- TrialORIENT-32
Shares Sintilimab, Hepatocellular carcinoma.
cancers
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
ApprovedMonoclonal antibody (anti-PD-1, IgG4)
Sintilimab · Tyvyt
trials
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in PartCVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular CarcinomaStudy of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
trx.com.tw · 1
A source that has moved or gone is reported by the weekly link check. /audit/